8-Nov-2024 6:00 AM CST - Business Wire Fulgent Reports Third Quarter 2024 Financial Results Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million
5-Nov-2024 7:00 AM CST - Business Wire Fulgent to Participate in Upcoming Conferences Fulgent Genetics, Inc. (NASDAQ:FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 12th at 2:45 PM Pacific Time Piper Sandler 36th Annual Healthcare Conference on Wednesday, Decemb
17-Oct-2024 3:05 PM CST - Business Wire Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024 Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer que
8-Nov-2024 6:00 AM CST - Business Wire Fulgent Reports Third Quarter 2024 Financial Results Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Results: Total Revenue of $71.7 million Core Revenue1 grew 9% year-over-year to $71.7 million GAAP loss of $14.6 million, or ($0.48) per share Non-GAAP income of $9.4 million
5-Nov-2024 7:00 AM CST - Business Wire Fulgent to Participate in Upcoming Conferences Fulgent Genetics, Inc. (NASDAQ:FLGT) (Fulgent, or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences: UBS Global Healthcare Conference on Tuesday, November 12th at 2:45 PM Pacific Time Piper Sandler 36th Annual Healthcare Conference on Wednesday, Decemb
17-Oct-2024 3:05 PM CST - Business Wire Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024 Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer que
